Dr. Brian Burton says he hears these stories often, though much is still unknown. Mom of three Jessica Kelliher says she pays about $250 a month for her drug.
Recap by typeshit. Full story at WOAI.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
A short clip of Rosie O'Donnell discussing the tirzepatide drug Mounjaro. Few details are given beyond the title.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
UMB posted a recorded session on its YouTube channel covering how GLP-1 medicines work, plus their benefits and risks.
Heal and Clinic notes that semaglutide acts on GLP-1 alone while tirzepatide targets both GIP and GLP-1, and says no single choice suits everyone.
Loading…